Sustained intra-articular delivery of IL-1Ra from a thermally-responsive elastin-like polypeptide as a therapy for post-traumatic arthritis

European Cells and Materials

Volumn 29, Issue , 2015, Pages 124-140

  Kimmerling, K A ^a,b   Furman, B D ^a   Mangiapani, D S ^a   Moverman, M A ^b   Sinclair, S M ^b   Huebner, J L ^c   Chilkoti, A ^b   Kraus, V B ^a,c   Setton, L A ^a,b   Guilak, F ^a,b   Olson, Steven A ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b USA   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Arthritis; Cartilage; Drug delivery; Inflammation; Murine model

Indexed keywords

CROSS LINKED ELASTIN LIKE POLYPEPTIDE; CYTOKINE; ETANERCEPT; INTERLEUKIN 1; POLYPEPTIDE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; CARTILAGE OLIGOMERIC MATRIX PROTEIN; DELAYED RELEASE FORMULATION; ELASTIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; PEPTIDE; STROMELYSIN; TUMOR NECROSIS FACTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ARTICULAR CARTILAGE; BONE STRUCTURE; CARTILAGE DEGENERATION; CONTROLLED STUDY; ENCAPSULATION; JOINT DEGENERATION; JOINT FRACTURE; MALE; MOUSE; NONHUMAN; PATHOGENESIS; POSTTRAUMATIC ARTHROPATHY; SUSTAINED RELEASE PREPARATION; SYNOVITIS; TEMPERATURE; TIBIA FRACTURE; ADMINISTRATION AND DOSAGE; AMINO ACID SEQUENCE; ANIMAL; ANTAGONISTS AND INHIBITORS; ARTHRITIS, EXPERIMENTAL; BLOOD; C57BL MOUSE; CHEMISTRY; COMPLICATION; DELAYED RELEASE FORMULATION; DRUG DELIVERY SYSTEM; DRUG EFFECTS; INJURIES; INJURY; INTRAARTICULAR DRUG ADMINISTRATION; METABOLISM; MICRO-COMPUTED TOMOGRAPHY; MOLECULAR GENETICS; PHARMACOLOGY; PROCEDURES; RADIOGRAPHY; SYNOVIAL FLUID; TIME FACTOR; TREATMENT OUTCOME;

AMINO ACID SEQUENCE; ANIMALS; ARTHRITIS, EXPERIMENTAL; CARTILAGE OLIGOMERIC MATRIX PROTEIN; CARTILAGE, ARTICULAR; DELAYED-ACTION PREPARATIONS; DRUG DELIVERY SYSTEMS; ELASTIN; INJECTIONS, INTRA-ARTICULAR; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1; MALE; MATRIX METALLOPROTEINASE 3; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; PEPTIDES; SYNOVIAL FLUID; TEMPERATURE; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; WOUNDS AND INJURIES; X-RAY MICROTOMOGRAPHY;

EID: 84922056946     PISSN: 14732262     EISSN: None     Source Type: Journal    
DOI: 10.22203/eCM.v029a10     Document Type: Article

References (87)

1. Abramson SB, Yazici Y (2006) Biologics in development for rheumatoid arthritis: relevance to osteoarthritis. Adv Drug Deliv Rev 58: 212-225.
2. Adams SB Jr, Shamji MF, Nettles DL, Hwang P, Setton LA (2009) Sustained release of antibiotics from injectable and thermally responsive polypeptide depots. J Biomed Mater Res B Appl Biomater 90: 67-74.
3. Allen KD, Adams SB, Setton LA (2010) Evaluating intra-articular drug delivery for the treatment of osteoarthritis in a rat model. Tissue Eng Part B Rev 16: 81-92.
4. Allen KD, Adams SB Jr, Mata BA, Shamji MF, Gouze E, Jing L, Nettles DL, Latt LD, Setton LA (2011) Gait and behavior in an IL1beta-mediated model of rat knee arthritis and effects of an IL1 antagonist. J Orthop Res 29: 694-703.
5. Amiram M, Luginbuhl KM, Li X, Feinglos MN, Chilkoti A (2013) A depot-forming glucagon-like peptide-1 fusion protein reduces blood glucose for five days with a single injection. J Control Release 172: 144-151.
6. Bathon JM, Fleischmann RM, Van der Heijde D, Tesser JR, Peloso PM, Chon Y, White B (2006) Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritis. J Rheumatol 33: 234-243.
7. Betre H, Liu W, Zalutsky MR, Chilkoti A, Kraus VB, Setton LA (2006a) A thermally responsive biopolymer for intra-articular drug delivery. J Control Release 115: 175-182.
8. Bigoni M, Sacerdote P, Turati M, Franchi S, Gandolla M, Gaddi D, Moretti S, Munegato D, Augusti CA, Bresciani E, Omeljaniuk RJ, Locatelli V, Torsello A (2013) Acute and late changes in intraarticular cytokine levels following anterior cruciate ligament injury. J Orthop Res 31: 315-321.
9. Bliddal H, Terslev L, Qvistgaard E, Konig M, Holm CC, Rogind H, Boesen M, Danneskiold-Samsoe B, Torp-Pedersen S (2006) A randomized, controlled study of a single intra-articular injection of etanercept or glucocorticosteroids in patients with rheumatoid arthritis. Scand J Rheumatol 35: 341-345.
10. Boesen M, Boesen L, Jensen KE, Cimmino MA, Torp-Pedersen S, Terslev L, Koenig M, Danneskiold-Samsoe B, Rogind H, Bliddal H (2008) Clinical outcome and imaging changes after intraarticular (IA) application of etanercept or methylprednisolone in rheumatoid arthritis: magnetic resonance imaging and ultrasound-Doppler show no effect of IA injections in the wrist after 4 weeks. J Rheumatol 35: 584-591.
11. Bresnihan B, Alvaro-Gracia JM, Cobby M, Doherty M, Domljan Z, Emery P, Nuki G, Pavelka K, Rau R, Rozman B, Watt I, Williams B, Aitchison R, McCabe D, Musikic P (1998) Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 41: 2196-2204.
12. Brown TD, Johnston RC, Saltzman CL, Marsh JL, Buckwalter JA (2006) Posttraumatic osteoarthritis: a first estimate of incidence, prevalence, and burden of disease. J Orthop Trauma 20: 739-744.
13. Buckwalter JA, Brown TD (2004) Joint injury, repair, and remodeling: roles in post-traumatic osteoarthritis. Clin Orthop Relat Res 423: 7-16.
14. Cameron M, Buchgraber A, Passler H, Vogt M, Thonar E, Fu F, Evans CH (1997) The natural history of the anterior cruciate ligament-deficient knee. Changes in synovial fluid cytokine and keratan sulfate concentrations. Am J Sports Med 25: 751-754.
15. Caron JP, Fernandes JC, Martel-Pelletier J, Tardif G, Mineau F, Geng C, Pelletier JP (1996) Chondroprotective effect of intraarticular injections of interleukin-1 receptor antagonist in experimental osteoarthritis. Suppression of collagenase-1 expression. Arthritis Rheum 39: 1535-1544.
16. Chevalier X, Giraudeau B, Conrozier T, Marliere J, Kiefer P, Goupille P (2005) Safety study of intraarticular injection of interleukin 1 receptor antagonist in patients with painful knee osteoarthritis: a multicenter study. J Rheumatol 32: 1317-1323.
17. Chevalier X, Goupille P, Beaulieu AD, Burch FX, Bensen WG, Conrozier T, Loeuille D, Kivitz AJ, Silver D, Appleton BE (2009) Intraarticular injection of anakinra in osteoarthritis of the knee: a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 61: 344-352.
18. Chilkoti A, Dreher MR, Meyer DE (2002a) Design of thermally responsive, recombinant polypeptide carriers for targeted drug delivery. Adv Drug Deliv Rev 54: 1093-1111.
19. Chilkoti A, Dreher MR, Meyer DE, Raucher D (2002b) Targeted drug delivery by thermally responsive polymers. Adv Drug Deliv Rev 54: 613-630.
20. Cole P, Levy B, Schatzker J, Watson JT (2009) Tibial plateau fractures. In: Browner BD, Levine AM, Jupiter JB, Trafton PG (eds) Skeletal Trauma: Basic Science, Management, and Reconstruction, Saunders/Elsevier, Philadelphia, pp 2201-2288.
21. Elsaid KA, Machan JT, Waller K, Fleming BC, Jay GD (2009) The impact of anterior cruciate ligament injury on lubricin metabolism and the effect of inhibiting tumor necrosis factor alpha on chondroprotection in an animal model. Arthritis Rheum 60: 2997-3006.
22. Evans CH, Kraus VB, Setton LA (2014) Progress in intra-articular therapy. Nat Rev Rheumatol 10: 11-22.
23. Fazzalari NL (2011) Bone fracture and bone fracture repair. Osteoporos Int 22: 2003-2006.
24. Fernandes JC, Martel-Pelletier J, Pelletier JP (2002) The role of cytokines in osteoarthritis pathophysiology. Biorheology 39: 237-246.
25. Fiocco U, Sfriso P, Oliviero F, Roux-Lombard P, Scagliori E, Cozzi L, Lunardi F, Calabrese F, Vezzu M, Dainese S, Molena B, Scanu A, Nardacchione R, Rubaltelli L, Dayer JM, Punzi L (2010) Synovial effusion and synovial fluid biomarkers in psoriatic arthritis to assess intraarticular tumor necrosis factor-alpha blockade in the knee joint. Arthritis Res Ther 12: R148.
26. Fleischmann R (2006) Anakinra in the treatment of rheumatic disease. Expert Rev Clin Immunol 2: 331-340.
27. Fleischmann RM, Baumgartner SW, Tindall EA, Weaver AL, Moreland LW, Schiff MH, Martin RW, Spencer-Green GT (2003a) Response to etanercept (Enbrel) in elderly patients with rheumatoid arthritis: a retrospective analysis of clinical trial results. J Rheumatol 30: 691-696.
28. Fleischmann RM, Schechtman J, Bennett R, Handel ML, Burmester GR, Tesser J, Modafferi D, Poulakos J, Sun G (2003b) Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trial. Arthritis Rheum 48: 927-934.
29. Fleischmann R, Baumgartner SW, Weisman MH, Liu T, White B, Peloso P (2006a) Long term safety of etanercept in elderly subjects with rheumatic diseases. Ann Rheum Dis 65: 379-384.
30. Fleischmann RM, Tesser J, Schiff MH, Schechtman J, Burmester GR, Bennett R, Modafferi D, Zhou L, Bell D, Appleton B (2006b) Safety of extended treatment with anakinra in patients with rheumatoid arthritis. Ann Rheum Dis 65: 1006-1012.
31. Fukui N, Purple CR, Sandell LJ (2001) Cell biology of osteoarthritis: the chondrocyte's response to injury. Curr Rheumatol Rep 3: 496-505.
32. Furman BD, Olson SA, Guilak F (2006) The development of posttraumatic arthritis after articular fracture. J Orthop Trauma 20: 719-725.
33. Furman BD, Strand J, Hembree WC, Ward BD, Guilak F, Olson SA (2007) Joint degeneration following closed intraarticular fracture in the mouse knee: a model of posttraumatic arthritis. J Orthop Res 25: 578-592.
34. Furman BD, Kimmerling KA, Huebner JL, Kraus VB, Guilak F, Olson SA (2014a) Articular fracture in the ankle results in increased acute local inflammation. Transactions of the Annual Meeting of the Orthopaedic Research Society, New Orleans, LA, p 1069.
35. Furman BD, Mangiapani DS, Zeitler E, Bailey KN, Horne PH, Huebner JL, Kraus VB, Guilak F, Olson SA (2014b) Targeting pro-inflammatory cytokines following joint injury: acute intra-articular inhibition of interleukin-1 following knee injury prevents post-traumatic arthritis. Arthritis Res Ther 16: R134.
36. Gerstenfeld LC, Cho TJ, Kon T, Aizawa T, Tsay A, Fitch J, Barnes GL, Graves DT, Einhorn TA (2003) Impaired fracture healing in the absence of TNF-alpha signaling: the role of TNF-alpha in endochondral cartilage resorption. J Bone Miner Res 18: 1584-1592.
37. Gorth DJ, Mauck RL, Chiaro JA, Mohanraj B, Hebela NM, Dodge GR, Elliott DM, Smith LJ (2012) IL-1ra delivered from poly(lactic-co-glycolic acid) microspheres attenuates IL-1beta-mediated degradation of nucleus pulposus in vitro. Arthritis Res Ther 14: R179.
38. Guler-Yuksel M, Allaart CF, Watt I, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, van Schaardenburg D, van Krugten MV, Dijkmans BA, Huizinga TW, Lems WF, Kloppenburg M (2010) Treatment with TNF-alpha inhibitor infliximab might reduce hand osteoarthritis in patients with rheumatoid arthritis. Osteoarthritis Cartilage 18: 1256-1262.
39. Hazell PK, Dent C, Fairclough JA, Bayliss MT, Hardingham TE (1995) Changes in glycosaminoglycan epitope levels in knee joint fluid following injury. Arthritis Rheum 38: 953-959.
40. Higuchi H, Shirakura K, Kimura M, Terauchi M, Shinozaki T, Watanabe H, Takagishi K (2006) Changes in biochemical parameters after anterior cruciate ligament injury. Int Orthop 30: 43-47.
41. Irie K, Uchiyama E, Iwaso H (2003) Intraarticular inflammatory cytokines in acute anterior cruciate ligament injured knee. Knee 10: 93-96.
42. Johnsen AK, Schiff MH, Mease PJ, Moreland LW, Maier AL, Coblyn JS, Helfgott SM, Leff JA, Weinblatt ME (2006) Comparison of 2 doses of etanercept (50 vs. 100 mg) in active rheumatoid arthritis: a randomized double blind study. J Rheumatol 33: 659-664.
43. Kavanaugh A, Klareskog L, van der Heijde D, Li J, Freundlich B, Hooper M (2008) Improvements in clinical response between 12 and 24 weeks in patients with rheumatoid arthritis on etanercept therapy with or without methotrexate. Ann Rheum Dis 67: 1444-1447.
44. Kraus VB, Birmingham J, Stabler TV, Feng S, Taylor DC, Moorman CT 3rd, Garrett WE, Toth AP (2012) Effects of intraarticular IL1-Ra for acute anterior cruciate ligament knee injury: a randomized controlled pilot trial (NCT00332254). Osteoarthritis Cartilage 20: 271-278.
45. Krieckaert CL, Jamnitski A, Nurmohamed MT, Kostense PJ, Boers M, Wolbink G (2012) Comparison of long-term clinical outcome with etanercept treatment and adalimumab treatment of rheumatoid arthritis with respect to immunogenicity. Arthritis Rheum 64: 3850-3855.
46. Kubota E, Imamura H, Kubota T, Shibata T, Murakami K (1997) Interleukin 1 beta and stromelysin (MMP3) activity of synovial fluid as possible markers of osteoarthritis in the temporomandibular joint. J Oral Maxillofac Surg 55: 20-27.
47. Lange J, Sapozhnikova A, Lu C, Hu D, Li X, Micalu T, Marcucio RS (2010) Action of IL-1β during fracture healing. J Orthop Res 28: 778-784.
48. Larsen C, Ostergaard J, Larsen SW, Jensen H, Jacobsen S, Lindegaard C, Andersen PH (2008) Intra-articular depot formulation principles: role in the management of postoperative pain and arthritic disorders. J Pharm Sci 97: 4622-4654.
49. Lawrence RC, Felson DT, Helmick CG, Arnold LM, Choi H, Deyo RA, Gabriel S, Hirsch R, Hochberg MC, Hunder GG, Jordan JM, Katz JN, Kremers HM, Wolfe F, National Arthritis Data Workgroup (2008) Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum 58: 26-35.
50. Lewis JS Jr, Furman BD, Zeitler E, Huebner JL, Kraus VB, Guilak F, Olson SA (2013) Genetic and cellular evidence of decreased inflammation associated with reduced post-traumatic arthritis in MRL/MpJ mice. Arthritis Rheum 65: 660-670.
51. Lim DW, Nettles DL, Setton LA, Chilkoti A (2007) Rapid cross-linking of elastin-like polypeptides with (hydroxymethyl)phosphines in aqueous solution. Biomacromolecules 8: 1463-1470.
52. Lim DW, Nettles DL, Setton LA, Chilkoti A (2008) In situ cross-linking of elastin-like polypeptide block copolymers for tissue repair. Biomacromolecules 9: 222-230.
53. Lindhorst E, Vail TP, Guilak F, Wang H, Setton LA, Vilim V, Kraus VB (2000) Longitudinal characterization of synovial fluid biomarkers in the canine meniscectomy model of osteoarthritis. J Orthop Res 18: 269-280.
54. MacEwan SR, Chilkoti A (2009) Elastin-like polypeptides: biomedical applications of tunable biopolymers. Peptide Sci 94: 60-77.
55. Magnano MD, Chakravarty EF, Broudy C, Chung L, Kelman A, Hillygus J, Genovese MC (2007) A pilot study of tumor necrosis factor inhibition in erosive/inflammatory osteoarthritis of the hands. J Rheumatol 34: 1323-1327.
56. Mahmoud RK, El-Ansary AK, El-Eishi HH, Kamal HM, El-Saeed NH (2005) Matrix metalloproteinases MMP-3 and MMP-1 levels in sera and synovial fluids in patients with rheumatoid arthritis and osteoarthritis. Ital J Biochem 54: 248-257.
57. Mangiapani DS, Zeitler E, Furman BD, Huebner JL, Kraus VB, Guilak F, Olson SA (2012) Inhibition of interleukin-1 prevents post-traumatic arthritis following articular fracture in the mouse knee. Transactions of the Annual Meeing of the Orthopaedic Research Society, San Francisco, CA, p 711.
58. Marks PH, Donaldson ML (2005) Inflammatory cytokine profiles associated with chondral damage in the anterior cruciate ligament-deficient knee. Arthroscopy 21: 1342-1347.
59. McEvoy G (2006) AHFS Drug Information 2006. American Society of Health-System Pharmacists, Bethesda, MD.
60. McNulty AL, Rothfusz NE, Leddy HA, Guilak F (2013) Synovial fluid concentrations and relative potency of interleukin-1 alpha and beta in cartilage and meniscus degradation. J Orthop Res 31: 1039-1045.
61. Megeed Z, Cappello J, Ghandehari H (2002) Genetically engineered silk-elastinlike protein polymers for controlled drug delivery. Adv Drug Deliv Rev 54: 1075-1091.
62. Meyer DE, Chilkoti A (2002) Genetically encoded synthesis of protein-based polymers with precisely specified molecular weight and sequence by recursive directional ligation: examples from the elastin-like polypeptide system. Biomacromolecules 3: 357-367.
63. Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, Weaver AL, Keystone EC, Furst DE, Mease PJ, Ruderman EM, Horwitz DA, Arkfeld DG, Garrison L, Burge DJ, Blosch CM, Lange ML, McDonnell ND, Weinblatt ME (1999) Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 130: 478-486.
64. Mountziaris PM, Mikos AG (2008) Modulation of the inflammatory response for enhanced bone tissue regeneration. Tissue Eng Part B Rev 14: 179-186.
65. Nettles DL, Chilkoti A, Setton LA (2010) Applications of elastin-like polypeptides in tissue engineering. Adv Drug Deliv Rev 62: 1479-1485.
66. Nuki G, Bresnihan B, Bear MB, McCabe D, European Group Of Clinical Investigators (2002) Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46: 2838-2846.
67. Patzkowski JC, Rivera JC, Ficke JR, Wenke JC (2012) The changing face of disability in the US Army: the Operation Enduring Freedom and Operation Iraqi Freedom effect. J Am Acad Orthop Surg 20 Suppl 1: S23-30.
68. Ribbens C, Martin y Porras M, Franchimont N, Kaiser MJ, Jaspar JM, Damas P, Houssiau FA, Malaise MG (2002) Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment. Ann Rheum Dis 61: 161-166.
69. Rivera JC, Wenke JC, Buckwalter JA, Ficke JR, Johnson AE (2012) Posttraumatic osteoarthritis caused by battlefield injuries: the primary source of disability in warriors. J Am Acad Orthop Surg 20 Suppl 1: S64-69.
70. Roux CH, Breuil V, Valerio L, Amoretti N, Brocq O, Albert C, Grisot C, Allam Y, Chevalier P, Pradier C, Euller-Ziegler L (2011) Etanercept compared to intraarticular corticosteroid injection in rheumatoid arthritis: double-blind, randomized pilot study. J Rheumatol 38: 1009-1011.
71. Sarahrudi K, Thomas A, Mousavi M, Kaiser G, Kottstorfer J, Kecht M, Hajdu S, Aharinejad S (2011) Elevated transforming growth factor-beta 1 (TGF-beta1) levels in human fracture healing. Injury 42: 833-837.
72. Saxne T, Heinegard D (1992) Cartilage oligomeric matrix protein: a novel marker of cartilage turnover detectable in synovial fluid and blood. Br J Rheumatol 31: 583-591.
73. Seifer DR, Furman BD, Guilak F, Olson SA, Brooks SC 3rd, Kraus VB (2008) Novel synovial fluid recovery method allows for quantification of a marker of arthritis in mice. Osteoarthritis Cartilage 16: 1532-1538.
74. Shamji MF, Betre H, Kraus VB, Chen J, Chilkoti A, Pichika R, Masuda K, Setton LA (2007) Development and characterization of a fusion protein between thermally responsive elastin-like polypeptide and interleukin-1 receptor antagonist: sustained release of a local antiinflammatory therapeutic. Arthritis Rheum 56: 3650-3661.
75. Sward P, Frobell R, Englund M, Roos H, Struglics A (2012) Cartilage and bone markers and inflammatory cytokines are increased in synovial fluid in the acute phase of knee injury (hemarthrosis)-a cross-sectional analysis. Osteoarthritis Cartilage 20: 1302-1308.
76. Tejeda-Montes E, Smith KH, Poch M, Lopez-Bosque MJ, Martin L, Alonso M, Engel E, Mata A (2012) Engineering membrane scaffolds with both physical and biomolecular signaling. Acta Biomater 8: 998-1009.
77. Trabbic-Carlson K, Setton LA, Chilkoti A (2003) Swelling and mechanical behaviors of chemically cross-linked hydrogels of elastin-like polypeptides. Biomacromolecules 4: 572-580.
78. Urry DW (1992) Free energy transduction in polypeptides and proteins based on inverse temperature transitions. Prog Biophys Mol Biol 57: 23-57.
79. Urry DW (1997) Physical chemistry of biological free energy transduction as demonstrated by elastic protein-based polymers. J Phys Chem B 101: 11007-11028.
80. Urry DW, Pattanaik A, Xu J, Woods TC, McPherson DT, Parker TM (1998) Elastic protein-based polymers in soft tissue augmentation and generation. J Biomater Sci Polym Ed 9: 1015-1048.
81. Zimmermann G, Henle P, Kusswetter M, Moghaddam A, Wentzensen A, Richter W, Weiss S (2005) TGF-beta1 as a marker of delayed fracture healing. Bone 36: 779-785.
82. Zimmermann G, Moghaddam A, Reumann M, Wangler B, Breier L, Wentzensen A, Henle P, Weiss S (2007) TGF-β1 als pathophysiologischer Faktor bei der Frakturheilung. [TGF-beta1 as a pathophysiological factor in fracture healing.] Unfallchirurg 110: 130-136.
83. Zwerina J, Hayer S, Tohidast-Akrad M, Bergmeister H, Redlich K, Feige U, Dunstan C, Kollias G, Steiner G, Smolen J, Schett G (2004) Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction. Arthritis Rheum 50: 277-290.
84. Betre H, Ong SR, Guilak F, Chilkoti A, Fermor B, Setton LA (2006b) Chondrocytic differentiation of human adipose-derived adult stem cells in elastin-like polypeptide. Biomaterials 27: 91-99.
85. Diekman BO, Wu CL, Louer CR, Furman BD, Huebner JL, Kraus VB, Olson SA, Guilak F (2013) Intra-articular delivery of purified mesenchymal stem cells from C57BL/6 or MRL/MpJ superhealer mice prevents posttraumatic arthritis. Cell Transplant 22: 1395-1408.
86. Nijkamp FP, Parnham MJ (2005) Principles of Immunopharmacology. Birkhäuser Basel, Basel, Chapter C13, p 535.
87. Piccolo GL, Kaplan DS, Batchelder KF, Kapur R, Kotz RM (1993) Biotechnology-derived biomaterials modulate host cell reactive oxygen production as measured by chemiluminescence. Transactions of the Annual Meeting of the Society for Biomaterials, Birmingham, AL.